STAT
APRIL 5, 2024
sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira , STAT reports. That led to less uptake of biosimilar versions of Humira in the U.S., IPV is made by only two companies — Sanofi Pasteur and Serum Institute of India, which started its supplies in 2021.
pharmaphorum
JANUARY 28, 2021
It has been five years since the first biosimilar launched in United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients manage and treat difficult illnesses such as cancer, rheumatoid arthritis, and other life-altering diseases. million patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Safe Biologics
DECEMBER 19, 2023
The guidance removed the interchangeability statement from the product label/package insert of interchangeable biosimilars. state law, only interchangeable biosimilars may be substituted by a pharmacist without contacting the prescriber. The agency has approved 44 biosimilar products, including seven interchangeable biosimilars.
Med Ed 101
OCTOBER 24, 2021
FDA-approved biosimilars have been compared to a biologic and shown to be highly similar in structure and function. At the time this article was written, there are currently 31 FDA-approved biosimilars. The post Biosimilar Updates 2021 appeared first on Med Ed 101.
STAT
APRIL 25, 2024
In 2021 alone, the use of generic and biosimilar drugs saved $373 billion in health expenditures. More than 90% of prescriptions filled that year were for generics or biosimilars, up from just over 18% the year that Hatch-Waxman was passed. Today, however, generic drugs seem to be a victim of their success.
Safe Biologics
JANUARY 6, 2024
In November, the Centers for Medicare and Medicaid Services (CMS) announced a Proposed Rule that would permit Medicare Part D plan sponsors to substitute non-interchangeable biosimilars in place of the biologic medicines now used to treat many chronic conditions such as rheumatoid arthritis, Crohn’s disease and cancer.
Big Molecule Watch
OCTOBER 11, 2023
FDA grants interchangeable designation to Pfizer’s adaliumumab biosimilar – On October 5, 2023, Pfizer Inc. Food and Drug Administration (FDA) has designated ABRILADA (adalimumab-afzb) as an interchangeable biosimilar to HUMIRA (adalimumab). The post Recent Adalimumab Biosimilar Developments appeared first on Big Molecule Watch.
Expert insights. Personalized for you.
221 
Let's personalize your content